ERBB2 and breast carcinoma: From the application view, the stimuli-responsive nanocarriers have attracted broad attention, as the stimuli could be existed/generated in most of the tumors, while the cancer cell-specific receptors were reported to be expressed only on partial cancer cells (e.g., the expression of Her2/neu was only found in less than 25% of breast cancer patients) 20, which may require preselection of receptors for the application of ligand-installed nanocarriers.